![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Lotus will gain access to Teva’s ophthalmic and respiratory portfolio, including NATEAR (hydroxypropyl methylcellulose) used as artificial tears to prevent conjunctival and corneal damage.
Lead Product(s): Hypromellose
Therapeutic Area: Ophthalmology Product Name: Natear
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lotus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 06, 2024